1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023

Summary

GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Of the 7MM forecast for acute coronary syndrome, the US market dominates the other six countries in sales for every class and brand of drug, by a very large margin. The statin share can predominantly be attributed to sales volume as most statins, with the exception of Crestor, are available as inexpensive generics. Contrarily, the large market share from the ARBs is due to the relatively high cost of therapy and the presence of branded options still on the market.

Scope

- Overview of ACS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US ACS market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US

Table Of Contents

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 14
2.1 Catalyst 14
2.2 Related Reports 15
2.3 Upcoming Related Reports 17
3 Disease Overview 18
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 23
3.1.3 Prognosis 24
3.1.4 Quality of Life 25
3.2 Symptoms 25
4 Disease Management 27
4.1 Treatment Overview 27
4.2 US 31
4.2.1 Diagnosis 31
4.2.2 Clinical Practice 32
5 Competitive Assessment 34
5.1 Overview 34
5.2 Strategic Competitor Assessment 35
5.3 Product Profiles 40
5.3.1 Fibrinolytic (Thrombolytic) Drugs - Tissue Plasminogen Activator (tPA) 40
5.3.2 Clopidogrel 44
5.3.3 Brilinta (ticagrelor) 48
5.3.4 Effient (prasugrel) 52
5.3.5 Integrilin (eptifibatide) 56
5.3.6 Warfarin 59
5.3.7 Angiomax (bivalirudin) 63
5.3.8 Arixtra (fondaparinux) and the Heparins 66
5.3.9 Statins - HMG-CoA Reductase Inhibitors 70
5.3.10 Beta-Adrenergic Receptor Antagonists (Beta Blockers) 82
5.3.11 Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors 85
6 Unmet Need and Opportunity 98
6.1 Overview 98
6.2 Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques 99
6.2.1 Unmet Need 99
6.2.2 Gap Analysis 100
6.2.3 Opportunity 100
6.3 Therapies that Treat Fibrotic Myocardium and Associated Comorbidities 101
6.3.1 Unmet Need 101
6.3.2 Gap Analysis 102
6.3.3 Opportunity 102
6.4 LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients 103
6.4.1 Unmet Need 103
6.4.2 Gap Analysis 105
6.4.3 Opportunity 107
6.5 Antidotes for New Oral Anticoagulants (NOACs) 107
6.5.1 Unmet Need 107
6.5.2 Gap Analysis 108
6.5.3 Opportunity 108
6.6 Blood-Thinning Agents with Significantly Reduced Bleeding Risks 109
6.6.1 Unmet Need 109
6.6.2 Gap Analysis 110
6.6.3 Opportunity 110
7 Pipeline Assessment 112
7.1 Overview 112
7.2 Clinical Trials by Phase and Trial Status 114
7.3 Promising Drugs in Clinical Development 116
7.3.1 Xarelto (rivaroxaban) 120
7.3.2 Cangrelor 128
7.3.3 Zontivity (vorapaxar) 134
7.3.4 Alirocumab (RGN727) 140
7.3.5 Evolocumab (AMG 145) 148
7.3.6 Bococizumab (PF-04950615) 157
7.3.7 Anacetrapib 162
7.3.8 Evacetrapib 169
7.3.9 Darapladib 173
8 Market Outlook 179
8.1 United States 179
8.1.1 Forecast 179
8.1.2 Key Events 184
8.1.3 Drivers and Barriers - Global Issues 185
8.1.4 United States - Drivers and Barriers 191
9 Appendix 194
9.1 Bibliography 194
9.2 Abbreviations 208
9.3 Methodology 213
9.4 Forecasting Methodology 213
9.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 213
9.4.2 Diagnosed Acute Coronary Syndrome Patients 214
9.4.3 Percent Drug-Treated Patients 215
9.4.4 Drugs Included in Each Therapeutic Class 215
9.4.5 Launch and Patent Expiry Dates 216
9.4.6 General Pricing Assumptions 217
9.4.7 Individual Drug Assumptions 217
9.4.8 Generic Erosion 226
9.4.9 Pricing of Pipeline Agents 226
9.5 Physicians and Specialists Included in this Study 227
9.6 About the Authors 230
9.6.1 Author 230
9.6.2 Reviewer 230
9.6.3 Global Head of Healthcare 231
9.7 About GlobalData 232
9.8 Disclaimer 232

1.1 List of Tables

Table 1: Antiplatelet Agents that Inhibit Platelet Activation 21
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade 21
Table 3: Symptoms of Acute Coronary Syndrome 26
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 30
Table 5: Most Prescribed Drugs for ACS by Class in the US, 2014 30
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014 39
Table 7: Commonly Used tPAs 42
Table 8: Product Profile - Tissue Plasminogen Activator (tPA) 42
Table 9: Fibrinolytics?SWOT Analysis, 2014 44
Table 10: Product Profile - Plavix (clopidogrel) 46
Table 11: Clopidogrel SWOT Analysis, 2014 48
Table 12: Product Profile - Brilinta (ticagrelor) 50
Table 13: Brilinta (ticagrelor) SWOT Analysis, 2014 51
Table 14: Product Profile - Effient (prasugrel) 54
Table 15: Effient (prasugrel) SWOT Analysis, 2014 56
Table 16: Product Profile - Integrilin (eptifibatide) 57
Table 17: Integrilin (eptifibatide) SWOT Analysis, 2014 59
Table 18: Product Profile - Warfarin 61
Table 19: Warfarin SWOT Analysis, 2014 63
Table 20: Product Profile - Angiomax 64
Table 21: Angiomax (bivalirudin) SWOT Analysis, 2014 65
Table 22: Product Profile - Arixtra (fondaparinux) 67
Table 23: Arixtra (fondaparinux sodium) SWOT Analysis, 2014 70
Table 24: Product Profile - Lipitor 72
Table 25: Lipitor (atorvastatin) SWOT Analysis, 2014 74
Table 26: Product Profile - Crestor (rosuvastatin) 76
Table 27: Crestor (rosuvastatin) SWOT Analysis, 2014 78
Table 28: Product Profile - Zocor (simvastatin) 79
Table 29: Zocor (simvastatin) SWOT Analysis, 2014 81
Table 30: Commonly Used Beta Blockers 82
Table 31: Product Profile - Beta Blockers 83
Table 32: Beta Blockers SWOT Analysis, 2014 84
Table 33: Product Profile - Tekturna (aliskiren) 86
Table 34: Tekturna (aliskiren) SWOT Analysis, 2014 88
Table 35: Commonly Used ACE Inhibitors 89
Table 36: Product Profile - ACE Inhibitors 89
Table 37: ACE Inhibitor?SWOT Analysis, 2014 91
Table 38: Commonly Used ARBs 92
Table 39: Product Profile - Angiotensin Receptor Blockers (ARBs) 92
Table 40: ARB SWOT Analysis, 2014 94
Table 41: Product Profile - Mineralocorticoid Receptor Antagonists (MRAs) 95
Table 42: MRA SWOT Analysis, 2014 97
Table 43: Unmet Need and Opportunity in Acute Coronary Syndrome 99
Table 44: Acute Coronary Syndrome - Clinical Trials by Phase and Status, 2014 115
Table 45: Acute Coronary Syndrome - Late-Stage Pipeline, 2014 118
Table 46: Comparison of Therapeutic Classes in Development for ACS, 2014 119
Table 47: Product Profile - Xarelto (rivaroxaban) 123
Table 48: Xarelto (rivaroxaban) SWOT Analysis, 2014 127
Table 49: Product Profile - Cangrelor 130
Table 50: Cangrelor SWOT Analysis, 2014 134
Table 51: Product Profile - Zontivity (vorapaxar) 136
Table 52: Vorapaxar SWOT Analysis, 2014 140
Table 53: Product Profile - Alirocumab (RGN727) 143
Table 54: Alirocumab SWOT Analysis, 2014 148
Table 55: Product Profile - Evolocumab (AMG 145) 151
Table 56: Phase III Clinical Trials of Evolocumab Reported by Amgen from Q4 2013 - Q1 2014 153
Table 57: Evolocumab SWOT Analysis, 2013 157
Table 58: Product Profile - Bococizumab (PF-04950615) 159
Table 59: Bococizumab (PF-04950615) SWOT Analysis, 2014 161
Table 60: Product Profile - Anacetrapib 164
Table 61: Anacetrapib SWOT Analysis, 2014 168
Table 62: Product Profile - Evacetrapib 170
Table 63: Evacetrapib SWOT Analysis, 2013 173
Table 64: Product Profile - Darapladib 175
Table 65: Darapladib SWOT Analysis, 2014 178
Table 66: Sales Forecasts ($m) for ACS in US, 2013-2023 181
Table 67: Key Events Impacting Sales for Acute Coronary Syndrome in the US, 2014 184
Table 68: Acute Coronary Syndrome Market - Drivers and Barriers, 2014 185
Table 69: Acute Coronary Syndrome Market - Drivers and Barriers in the US, 2014 191
Table 70: Key Launch Dates 216
Table 71: Key Patent Expiries 216
Table 72: Price Sources and Calculations, in US 217
Table 73: Physicians Surveyed, By Country 229

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 19
Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome 20
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 22
Figure 4: Electrocardiography in the Diagnosis of ACS 23
Figure 5: Acute Coronary Syndrome Therapeutics - Clinical Trials by Phase in the 7MM, 2014 116
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents for ACS, 2013-2023 120
Figure 7: Sales for Acute Coronary Syndrome in US by Drug Class, 2013-2023 183

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.